Rothblatt, United Therapeutics CEO, sells $5.1m in UTHR stock

Martine Rothblatt sold $5.1M of United Therapeutics (UTHR) shares on Mar 12 and Mar 16, 2026 at $532.16–$544.5849 and exercised options to acquire 9,500 shares at $146.03 ($1,387,285), leaving her with 294 direct shares; trades were under a 10b5-1 plan adopted Nov 7, 2025. United Therapeutics unveiled a $2.0B buyback program including a $1.5B accelerated share repurchase (Citibank) with $500M remaining, and NEJM-published Phase 3 TETON-2 results showed nebulized Tyvaso met its primary endpoint with significant lung-function improvement versus placebo at 52 weeks. Analysts reacted positively: TD Cowen retains a Buy with a $575 target and Cantor Fitzgerald raised its target to $625 (from $525) with an Overweight rating, indicating potential upside and likely stock movement.

Analysis

The ASR-heavy buyback changes the stock’s supply/demand dynamics more than headline EPS math: immediate share removal via ASR concentrates float and increases the sensitivity of the stock to incremental flows and options gamma. That makes the name structurally more volatile on volume prints—every 1% net buying could move the stock multiple points more than before—creating favorable conditions for tactical long gamma trades and risks for illiquid sellers.

Clinically, a positive inhaled therapy readthrough materially increases addressable market optionality but shifts the battle from drug efficacy to device manufacturing, payer coding, and physician adoption. Commercial execution risk is front-loaded (6–12 months) as manufacturing scale-up, supply chain for proprietary nebulizers, and favorable reimbursement codes become the real gating items; failure in any of these will compress projected peak sales materially even with positive efficacy.

Insider option exercises executed inside a rule-based plan lower the informational value of the selling, yet the combination of option exercise plus concentrated buyback creates a technical tug-of-war: near-term share removal supports price while continued long-term selling or hedging by insiders (or trusts) could cap the move. Key time horizons to watch: ASR unwind and volume profile (days–weeks), payer/labeling/commercial rollout (6–12 months), and market-share penetration against incumbent therapies (2–4 years).

Key Decisions for Investors

• Long UTHR equity (size 1–2% NAV): accumulate over the next 2–6 weeks post-ASR prints, target +35–50% upside over 12 months, hard stop 18–20% to limit headline/regulatory downside. Rationale: buyback-driven float contraction + clinical signal, asymmetric upside if commercial execution is clean.
• Call spread (levered directional): buy a 9–12 month UTHR call spread ~20–30% OTM (buy nearer OTM, sell farther OTM) sized to risk 0.5% NAV. Expected payoff 2–4x if uptake/regulatory catalysts materialize; max loss = premium paid. This captures upside while capping cost given increased volatility from ASR mechanics.
• Pair trade to isolate idiosyncratic execution (market-neutral): long UTHR / short IBB (or a diversified mid-cap pulmonary peer) 60/40 on dollar notional for 6–12 months. This isolates UTHR’s commercial/ASR upside while hedging sector/regulatory beta; expect positive performance if company converts trial wins into market share.
• Income/defensive collar for holders: for existing long positions, sell 3–6 month slightly OTM calls and buy protective puts (collar) to monetize elevated implied volatility around ASR/commercial update windows. This reduces upside but funds downside protection to ~-12–15% while collecting premium during a period of structurally higher gamma.